Close
CDMO Safety Testing 2026
Novotech

Eli Lilly to Open a Diabetes-Focused Research Center in China

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

AstraZeneca’s Baxfendy Wins FDA Approval for Uncontrolled Hypertension

AstraZeneca's hypertension drug baxdrostat, branded as Baxfendy, has received...

EU Advances Critical Medicines Act to Cut Import Reliance

The European Union has moved closer to implementing new...
- Advertisement -

Eli Lilly and Company announced plans to open a research center focused on diabetes in China, where the incidence of the disease has reached epidemic proportions. The center, to open in Shanghai in the second half of 2011, will focus on discovering new medicines to treat diabetes, and reflects both Lilly’s longstanding leadership in this disease area and the priority Lilly places on improving the health of the Chinese people. Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories said, We are establishing this research center, first and foremost, to meet the growing unmet medical needs of those living in China with diabetes. This center will complement our existing network of collaborations in China and also will enable us to further gain the insights of China’s talented scientists inside and outside of Lilly as we further explore a disease state in need of new and innovative therapies.

Jacques Tapiero, senior vice president and president of Lilly’s emerging markets business area said, Our strategy in China, and throughout the world, is to bring innovation to patients. By establishing a diabetes research center in China, Lilly will be better able to discover medicines that are well suited to the particular needs of patients with diabetes in China.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

AstraZeneca’s Baxfendy Wins FDA Approval for Uncontrolled Hypertension

AstraZeneca's hypertension drug baxdrostat, branded as Baxfendy, has received...

EU Advances Critical Medicines Act to Cut Import Reliance

The European Union has moved closer to implementing new...

Novartis Expands Radioligand Therapy Manufacturing in US

Swiss pharmaceutical company Novartis has started construction of a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป